FinRadar.ai (@StuckInStock) header
FinRadar.ai (@StuckInStock) profile picture

https://teapawt.net/t.co/0p5bqCiJAX is a deep analytics platform with sophisticated Macro/Micro/Technical/Fundamental actionable data to help you be on the right side of the market

Joined December 2010
Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)Photo by FinRadar.ai (@StuckInStock)
FinRadar.ai retweeted
$KURA PT 30 by JPM!
$KURA $MLYS $COGT $PRQR $NKTX getting cheap with those xbi dips.... ofc can get cheaper in this market so Slow DCA as usual!
5
3
1
38
15,525
FinRadar.ai retweeted
$PFE 3 insiders buying 6.8%. Dividend yield
$PFE INSIDER CLUSTER - 3 insiders BUYING Total: $3.0M (3 transactions) Net shares: 114.9K • BLAYLOCK RONALD E • BOURLA ALBERT • Buckley Mortimer J
1
2
1
6
9,402
FinRadar.ai retweeted
$PHVS Bullish chart on daily but no position! @StuckInStock
1
1
13
8,603
FinRadar.ai retweeted
2
2
1
23
11,483
FinRadar.ai retweeted
$ALMS Insider buying here! 276K shares at $5.25! many catalyst in Q1 2026!
$ALMS bullish technical signal triggered a few days ago. Heavy biotech funds interest as well, and key catalysts coming in psoriasis and Lupus in 2026 Hope all is well. finradar.ai/stock-research/?…
1
2
1
18
16,087
The full horror of $MRK $DSNKY Herthena-Lung02, via Tony Mok #ASCO25
17
14
3
63
22,205
Piper Sandler reitd $ATYR OW/$20, after🗣️w/ MGMT/learned add'l tidbits that=PS's confidence in efzofitimod's value prop—a stat sig separation in avg daily OCS dose reduction would be a clear win as it would lower the cumulative burden of steroids (as echoed by FDA's perspective):
1
7
17
4,565
FinRadar.ai retweeted
$TSVT Decent chart , had approval with $BMY in April, Decent insider buying by Casdin capital 4.9 and 5.1, baker bros in! CC: @StuckInStock
4
1
21
9,329
“Yo @Adrian_H and @jesse_brodkin, you did it!” $sava
$SAVA Why search for a new CEO? Just admit the whole company was based on a fraud, dissolve the company and move on... Remi Barbier resigns as President and CEO and from the Board of Directors. Lindsay Burns, Ph.D., SVP, Neuroscience, at Cassava is also to step down from her role with the Company, effective immediately.
1
1
5
1,760
Stanley Druckenmiller on Powell: "Don't go on 60 Minutes, you're not a rock star."
50
101
24
1,194
310,603
FinRadar.ai retweeted
$VTYX $100M PIPE $8.95
1
4
16
9,714
Replying to @StuckInStock
All these medtech stocks acting like Ozempic is going to cure every illness. It’s getting ridiculous
2
1
5
2,111
$AVRO AVROBIO to Explore Strategic Alternatives
2
5
2
17
13,212
Need more fertilizer to make this grow. $CORN.
1
3
3
1,503
FinRadar.ai retweeted
$TCRX baker bros!
New SC 13D/A from BAKER BROS. ADVISORS LP concerning $TCRX. See details at tinyurl.com/2olzrun3
2
2
16
10,893
FinRadar.ai retweeted
Cantor $PDSB PT25 interim data showed an est 12-month survival rate of 87% (PFS) of 10.4 months encouraging given poor prognosis these patients face. remain encouraged by safety profile of PDS0101 in combination with KEYTRUDA, with only 8% of patients experiencing a Grade 3AE
$PDSB ASCO ABSTRACT BREAKDOWN 1 let's look at the Abstract released earlier and do some comparison with $MRK Keytruda drug (blockbuster) generating $21 Billion sales alone in 2022. Keytruda Monotherapy data ORR 19%, PFS ~3 months, 49% (12 month survival) and median OS ~12 mos
5
9
2
58
59,011
FinRadar.ai retweeted
Failed data WVE and merger for CWBR
1
1
13
8,362